New RA drug enters first human safety trial
NCT ID NCT07234773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug, KT501, in 24 adults with moderate to severe rheumatoid arthritis (RA). The main goal is to check safety and how the body handles the drug after a single injection. Participants must have had RA for at least 6 months and not responded well to other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kali Study Site
RECRUITINGBayswater, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a traditional chinese herb tame stubborn rheumatoid arthritis?
- Could a common herb ease rheumatoid arthritis?
- New pill aims to tame rheumatoid arthritis inflammation
- Blood test could help rheumatoid arthritis patients safely reduce medication
- Will a new drug form work the same? study tests two versions of SKI-O-703
- Morning or evening? timing your RA pill could boost relief